Adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of recurrent high-grade glioma | Zendy

Nan Ji | Zendy; Danhui Weng | Zendy; Cang Liu | Zendy; Zheng Gu | Zendy; ShiZhang Chen | Zendy; Ying Guo | Zendy; Fan Zhong | Zendy; Xiao Wang | Zendy; Jianfei Chen | Zendy; Yanyan Zhao | Zendy; Jianfeng Zhou | Zendy; Jisheng Wang | Zendy; Ding Ma | Zendy; Ning Li | Zendy

Open Access

Adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of recurrent high-grade glioma

Author(s) -

Nan Ji,

Danhui Weng,

Cang Liu,

Zheng Gu,

ShiZhang Chen,

Ying Guo,

Fan Zhong,

Xiao Wang,

Jianfei Chen,

Yanyan Zhao,

Jianfeng Zhou,

Jisheng Wang,

Ding Ma,

Ning Li

Publication year - 2015

Publication title -

oncotarget

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.373

H-Index - 127

ISSN - 1949-2553

DOI - 10.18632/oncotarget.6737

Subject(s) - ganciclovir , medicine , progression free survival , glioma , adverse effect , clinical endpoint , herpes simplex virus , oncology , gastroenterology , clinical trial , surgery , chemotherapy , immunology , virus , human cytomegalovirus , cancer research

This randomized, open-label, multicenter, phase II clinical trial was conducted to assess the anti-tumor efficacy and safety of replication-deficient adenovirus mutant thymidine kinase (ADV-TK) in combination with ganciclovir administration in patients with recurrent high-grade glioma (HGG).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research